Valerie Vanhooren

Co-Founder & Chief Executive Officer ONA Therapeutics

Valerie is co-founder and CEO of Ona Therapeutics. Since 2019 she has guided the growth and development of Ona’s pipeline of first-in-class in ADCs and antibodies and secured over 35 million euros from a syndicate of international investors and non-dilutive grants. She has extensive experience in discovery and development of antibodies and protein conjugates for oncology. Prior to Ona she held leading R&D roles at SpliceBio and Ablynx (acquired by Sanofi), where she led drug development collaborative partnerships with multiple internationally operating pharmaceutical entities, including Merck and AbbVie. Valerie holds a PhD in Biotechnology from the University of Ghent, Belgium.

Seminars

Monday 8th March 2027
Panel Discussion: Financing the Next Generation of Safer, More Effective ADCs Through Biopharma Partnerships, Collaborations & Investment Strategies
4:10 pm

Discover what drives licensing decisions, investment strategies, and M&A activity, from making your ADC programmes attractive to where the next shift in the industry is heading. As large pharma companies increasingly compete for differentiated ADC platforms and clinical-stage assets, understanding the data, innovation, and risk factors behind successful deals has never been more important.

  • Discussion 1 – Building the Next Wave of ADC Drugs Through Biopharma Acquisitions & Technology Scouting
  • Discussion 2 – Turbocharging Biotech Innovation & Differentiation to Achieve Successful Fund Raising Rounds 
Headshot Of Valerie Vanhooren